title: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
abstract: Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efficacy and toxicity of a gemcitabine and cisplatin combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma.
  
  
  METHODS
  Gemcitabine 1250 mg m(-2) was administered on day 1 and day 8 and cisplatin 80 mg m(-2) was administered on day 1 in a 3-week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were observed (ORR 16%, 95% CI 1-31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred. Time to progression was 6 months (5-7 months) with a median survival from registration of 9.6 months (95% CI 8-12 months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule.
authors.affiliation: Rotterdam Oncological Thoracic Studygroup (ROTS), Department of Pulmonology, University Hospital Rotterdam, PO Box 5201, 3008 AE Rotterdam, The Netherlands.
authors.forename: J M W
authors.initials: JM
authors.lastname: van Haarst
authors.forename: P
authors.initials: P
authors.lastname: Baas
authors.forename: Ch
authors.initials: Ch
authors.lastname: Manegold
authors.forename: J H
authors.initials: JH
authors.lastname: Schouwink
authors.forename: J A
authors.initials: JA
authors.lastname: Burgers
authors.forename: H G
authors.initials: HG
authors.lastname: de Bruin
authors.forename: W J
authors.initials: WJ
authors.lastname: Mooi
authors.forename: R J
authors.initials: RJ
authors.lastname: van Klaveren
authors.forename: M J A
authors.initials: MJ
authors.lastname: de Jonge
authors.forename: J P
authors.initials: JP
authors.lastname: van Meerbeeck
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine